Articles tagged with Skin Tumors
A subset of breast cancer patients with HER-2 positive tumors may benefit from a combination of targeted treatments that avoid chemotherapy. The study, published in the Journal of Clinical Oncology, shows high efficacy in eradicating tumors and offers a groundbreaking approach to treatment without significant side effects.
Researchers developed a genetic mouse model of an incurable human cancer and demonstrated that blocking the CXCR4 receptor molecule can inhibit tumor development. The study revealed a potential target for therapy of malignant peripheral nerve sheath tumors, which are rare but highly aggressive and resistant to treatment.
Researchers discovered melanoma tumors deliberately create conditions to knock out the body's 'premier' immune defense and attract a weaker immune response. Higher levels of IgG4 antibodies in patients' blood are linked to a less favorable prognosis.
Researchers at Stanford University School of Medicine have identified a new way to block the Hedgehog pathway in skin cancers, which become resistant to treatment. The discovery offers a promising new approach for treating basal cell carcinoma and potentially improving patient outcomes.
Researchers identified a compound that blocks the expression of BLM protein, crucial for certain tumors to grow. The compound ML216 has the potential to stop tumor growth and is being explored as a treatment for osteosarcomas and soft tissue sarcomas.
A team of researchers at Yale University has identified four new genetic suspects linked to the origins and treatment of meningiomas. The study found that tumors mutated with these genes tend to be located in different areas of the brain, indicating their likelihood of becoming malignant.
Three independent studies demonstrate that hyperactivation of MAPK signaling pathways underlies NF1-associated disorders. Researchers found that inhibiting MEK and ERK can block the development of JMML, reduce the growth of peripheral nerve tumors, and ameliorate myeloproliferative disorders in NF1 mutant mice.
A new study found a four-fold increase in breast cancer incidence among women with neurofibromatosis-1, prompting recommendations for earlier screening. The researchers suggest annual manual breast exams and mammograms beginning at age 40 for this high-risk population.
Researchers at Indiana University School of Medicine have reported the first effective therapy for plexiform neurofibromas, tumors caused by neurofibromatosis type 1. The drug imatinib mesylate provided relief to a significant number of patients with NF1, improving symptoms and reducing tumor size.
Researchers found that mice exposed to a drug that increases TSLP levels are protected from developing skin tumors. Elevated TSLP also triggers an immune response that targets and destroys cancer cells. The study suggests that hyper-vigilance of the immune system may have benefits in fighting off skin cancer.
Melanoma cells can temporarily alter their external characteristics to become invisible to defense cells, allowing them to evade destruction. This knowledge forms an important foundation for improving combination therapies and may also be relevant to treatment with inhibitors of signal transmission in tumor cells.
A recent study reveals that basal-like breast tumors and ovarian tumors have similar genetic origins, suggesting potential for shared treatments. The research found unique genetic signatures within each subtype, highlighting the need for personalized cancer therapies.
A novel surgical approach has successfully removed a rare facial tumor and rebuilt a patient's lower jaw and mouth. The procedure involved removing the tumor and oral tongue while creating a fully functional lower jaw using dual microvascular free flaps.
Researchers at the University of Strathclyde have developed a new approach to delivering green tea extract, epigallocatechin gallate, directly to tumors. In initial laboratory tests, nearly two-thirds of treated tumors shrank or disappeared within one month with no side effects to normal tissues.
A study published in Cancer Research found that immune responses can be activated locally in the tumor microenvironment of melanoma skin metastases, contrary to previous thought. This discovery suggests that ectopic lymphoid structures may play a role in antimelanoma immune responses and has implications for treatment.
A new strategy for treating aggressive skin cancer involves inducing cell differentiation to prevent tumor growth. Researchers identified a molecular mechanism that promotes the disappearance and inhibition of skin squamous cell carcinoma development.
Researchers at LA BioMed are conducting a study to evaluate the effectiveness of an immune-stimulating topical cream called Imiquimod in treating melanoma. The study aims to assess how Imiquimod combats melanoma tumors at the genetic level and may lead to personalized immune therapy.
A recent study published in Nature Genetics provides evidence that genetic variations in the embryo may predispose individuals to cancer later in life. The study found that mutations in key genes were present in cells of patients with congenital skin lesions, suggesting an early origin for some tumors.
A new study published in the New England Journal of Medicine shows that vismodegib is effective in treating basal cell carcinoma, a common cancer caused by sun exposure. Researchers found that patients with Gorlin syndrome who took vismodegib developed an average of two new tumors per year, compared to 29 in those taking placebo.
A new study found that early childhood neglect may increase the risk of adult skin cancer recurrence, particularly in individuals who have experienced severe stress. The research suggests that early life experiences can affect immune response, making people more susceptible to certain types of cancers.
Researchers from NUS have discovered how a drug-lead compound named BPTES can deprive cancer cells of energy and stop them from growing into a tumour. Building on these findings, they also derived positive results for a novel dual-drug treatment regime that kills kidney and breast cancer cells more effectively.
Researchers discovered that topical application of imiquimod recruits plasmacytoid DCs to the tumor site, converting them into tumor-killing effector cells. A new mechanism for IFN-alpha suppression was also identified, targeting epigenetic regulation of nuclear cccDNA minichromosome.
Researchers found that imiquimod converts plasmacytoid DCs into tumor-killing effector cells, clearing tumors in a mouse model of melanoma. This discovery has implications for antitumor therapies targeting both skin cancers and other types.
Researchers at the University of Georgia have made a breakthrough in pig-induced pluripotent stem cells, showing they can safely incorporate into tissues without tumor formation. This finding has significant implications for stem cell therapies and potentially reduces the need for rodent-based models.
Researchers at Tel Aviv University have developed a radioactive wire that destroys tumors from the inside out, creating an immunity against cancer return. This innovative method, called DARTTM, has shown promising results in pre-clinical trials and is now being commercialized for clinical trials.
Researchers have found that sildenafil, the active ingredient in Viagra, can neutralize chronic inflammation caused by malignant melanoma, allowing tumor-specific T cells to function properly. This study suggests that Viagra may improve treatment results for people with melanoma by boosting antitumor immunity.
Researchers found that 2-deoxyglucose reduces tumor size in mice on either diet, while a carbohydrate-free diet led to greater tumor growth. This combination imposes energy stress on tumors and correlates with lower serum glucose levels.
A new study by Stanford researchers suggests that a novel mathematical formula can predict the success of certain cancer therapies by tracking the rate of tumor response during the first weeks of treatment. The formula, which uses advanced high-school-level math, identifies oncogene addiction in cancers, allowing for targeted therapies...
Researchers at University Medical Center Utrecht discovered that fish oil supplements containing omega-3 and omega-6 fatty acids can induce resistance to a broad spectrum of chemotherapies. The study found that the body's own protective substances, which are also present in fish oil, can block the effect of chemotherapy.
Researchers have identified a mechanism that explains how cancer cells change their appearance and progress from a solid state to a semiliquid mass. The study found that microRNA-200S inactivation leads to this transformation, allowing tumour cells to evade natural defences and invade neighbouring organs.
Researchers at Dana-Farber Cancer Institute found six abnormal genes that are both cancer-causing and metastasis-promoting in melanoma skin cancer. These genes can be used to predict whether human melanoma tumors are likely to spread, enabling doctors to cure the disease by intervening early.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
Researchers discovered a simple blood test for the protein melanoma-inhibitory activity (MIA) can indicate neurofibroma presence. The level of MIA depends on neurofibroma size and growth.
Researchers discovered c-JUN's ability to prevent methylation of p16INK4a and Cdk6, accelerating tumour formation and stabilizing these genes. This new function reveals a complex role for the protein in cancer development.
Researchers at Johns Hopkins Medicine have discovered a link between the slow growth of childhood brain tumors and a genetic process similar to that seen in skin moles. The study suggests that tumor-suppressor genes are activated, limiting tumor growth.
Researchers at UofL removed microRNA 21 from mice and found reduced skin tumor formation compared to control groups. The study suggests that miR-21 plays a role in cancer growth and that its removal increases the body's own tumor-suppressing ability.
Researchers have developed a new technique using light-sensitive molecules and antibodies to target tumour blood vessels, starving cancer cells of oxygen and nutrients. The treatment was shown to completely eradicate some models of skin cancer in clinical trials.
Researchers identified two previously unreported resistance mechanisms and found that resistance-conferring mutations can disappear after treatment is discontinued. Repeat biopsies provide critical information for guiding treatment decisions.
A nearly $2 million NIH grant will help Nationwide Children's Hospital investigate biomarkers linked to hemangioma development and outcome. The study aims to understand the role of oxidant production in hemangioma formation.
Researchers have developed a new method for imaging below the skin's surface using a liquid lens setup. This technology provides unprecedented images of tissue up to 1 millimeter deep, allowing for simpler and less invasive detection of skin lesions.
Researchers Bert Vogelstein and Jan Hoeijmakers received the Brupbacher Prize for their work on the genetic basis of tumor growth, shedding light on colorectal and skin cancers. Their findings have significant implications for understanding lifestyle-related causes of cancer and premature aging.
Researchers at Memorial Sloan-Kettering Cancer Center have developed a novel ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer. The first-in-human clinical trial aims to evaluate the distribution, tissue uptake, and safety of the particles in humans using PET imaging.
Researchers identified specific genetic mutations that predict tumor aggressiveness and treatment response in patients with neuroendocrine pancreatic cancer. The study's findings could lead to personalized cancer therapy and improved patient outcomes.
A study by researchers at Ohio State University found that an enzyme-armed virus can spread more effectively through brain tumors and improve survival rates. The enzyme helps the virus clear a path through protein molecules, allowing it to destroy cancer cells more efficiently.
Researchers have discovered MIC-1 as a regulator of angiogenesis, finding that it is present in high levels in 67% of melanoma patients. Targeting this protein can prevent blood vessel formation and decrease tumor development by up to 300%. This could lead to new therapeutic strategies for treating melanoma.
A Penn study found that HDAC enzymes are essential for proper skin formation and development. Inhibiting these enzymes may be able to shut down the growth of tumors resembling embryonic skin cells.
Researchers at Ohio State University found that an individual's normal genetic constitution plays a key role in driving changes in tumors during cancer development. The study compared genetic profiles of tumors from the same individual with those from other individuals, revealing similar yet distinct patterns of DNA changes.
Researchers at NC State University found that elevated SP2 protein in stem cells causes them to form cancerous tumors. Overproduction of SP2 stops stem cells from producing mature descendants, leading to uncontrolled proliferation and tumor formation.
A Stanford study finds that depletion of protein Perp, which hooks skin cells together, may be an early indicator of skin cancer development. The loss of Perp also promotes cancer by increasing inflammatory molecules and disrupting cell-cell adhesion.
Three USU doctoral students receive fellowships to study schistosomiasis, multiple sclerosis and tuberous sclerosis complex. The HJF program aims to develop new drug targets and treatments for these diseases.
Scientists at the University of Granada have developed a new therapy for skin and lung cancer using a suicide coliphage-gene, demonstrating effectiveness in vitro and in vivo. The treatment involves inducing cell death in tumour cells, potentially reducing the need for chemotherapy.
Researchers discovered an indirect approach to reducing JAK2 activity by targeting HSP90, which stabilized JAK2. This treatment normalized blood counts and improved survival in mouse models of myeloproliferative neoplasms. Inhibiting c-Met also decreased mTOR signaling and blocked cyst formation in a mouse model of autosomal dominant p...
Researchers at The Hormel Institute have found a link between capsaicin, a common ingredient in chili peppers, and the formation of skin cancer. Topical application of capsaicin induced tumors in mice, with higher and larger tumors forming in those without TRPV1 receptors.
Researchers have demonstrated the use of iron oxide nanoparticles to deliver antibodies to implanted brain tumors, enhancing tumor visibility via MRI while killing cancer cells. The particles also show potential for targeted therapy against glioblastoma multiforme, a common and aggressive primary brain tumor.
A new study found that an enriched environment can reduce cancer growth in mice by activating a nervous system pathway that decreases leptin levels, a hormone linked to appetite and cancer growth. The effect was observed in models of melanoma and colon cancer, with tumors reduced by up to 80% after three weeks of enrichment.
Researchers have identified biomarkers for life-threatening conditions in preterm infants, such as late-onset septicemia and necrotizing enterocolitis. Additionally, studies on leptin's role in childhood obesity and type 2 diabetes have shed light on the importance of hypothalamic signaling in preventing obesity development, while also...
Identification of IKKβ as a crucial signaling molecule in melanoma development may lead to new targeted therapies. The study suggests that treating patients with specific genetic profiles could enhance treatment efficacy.
Researchers have developed silica cages that can package anti-cancer antibodies, which significantly slow the growth of tumors and prolong the lives of mice. The treatment also reduces side effects compared to traditional intravenous drips.
The European Society for Medical Oncology has approved a personalized treatment for lung cancer, based on tumor characteristics. This approach promises to improve patient outcomes and reduce toxicity compared to traditional treatments.
Scientists discovered that beta-interferon inhibits tumor growth by blocking its connection to the blood circulatory system and reducing the production of growth factors. This effect was seen in mice where tumors grew slower and formed fewer metastases, highlighting a new potential target for cancer therapy.